A drug called zervimesine may offer a major breakthrough for people with dementia with Lewy bodies, a condition causing severe hallucinations and delusions. Cognition Therapeutics reports that a Phase 2 study showed the oral drug slowed psychosis progression by 89%. The FDA has signaled agreement on key trial design elements, paving the way for a Phase 3 study beginning mid-2027. Participants will take 100 mg of zervimesine once daily for nine months. The drug has shown a good safety profile so far. For the millions affected by Lewy body dementia — and their caregivers — this represents a potentially meaningful treatment option where few currently exist.
